CHO Pharma
CHO PHARMA is a glycoscience-centered biotech company that develops state-of-the-art glycoengineering technologies to create next-generation medicines. Our pioneering work has delivered CHOptimaxTM, a clinical-stage platform technology that provides a total solution for ADC development.
Using our proprietary donor substrates, CHOptimax™ enables one-step payload conjugation at the conserved Fc N-glycosylation site. Moreover, enhancements, including dual-payloads or higher DAR numbers, on such glycosite-specific ADCs can be easily achieved by CHOptimax™ as well. To creatively bring more promising medicines for more patients in need, we welcome any type of collaboration.
